A Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Participants With Diabetic Macular Edema Treated With Faricimab (ALTIMETER)

  • STATUS
    Recruiting
  • End date
    Dec 28, 2022
  • participants needed
    100
  • sponsor
    Hoffmann-La Roche
Updated on 30 June 2022

Summary

This is an exploratory, prospective, multicenter, open-label, single-arm, interventional, Phase IIb study designed to explore the associations over time between clinical assessments, multimodal imaging assessments, aqueous humor (AH) biomarker patterns, and genetic polymorphisms in participants with diabetic macular edema (DME) who are treated with faricimab.

Details
Condition Diabetic Macular Edema
Treatment Faricimab
Clinical Study IdentifierNCT04597918
SponsorHoffmann-La Roche
Last Modified on30 June 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Diagnosis of diabetes mellitus (Type 1 or Type 2), as defined by the World Health Organization (WHO) and/or American Diabetes Association
Hemoglobin A1c (HbA1c) ≤10%
Patients who are intravitreal (IVT) treatment-naïve in the study eye
Diabetic macular edema (DME) defined as macular thickening by spectral-domain optical coherence tomography (SD-OCT) involving the center of the macula. This inclusion criterion is to be assessed by the central reading center (CRC)
Decreased visual acuity (VA) attributable primarily to DME
Clear ocular media and adequate pupillary dilation to allow acquisition of good quality retinal images to confirm diagnosis

Exclusion Criteria

Currently untreated diabetes mellitus or previously untreated patients who initiated oral or injectable anti-diabetic medication within 3 months prior to Day 1
Any known hypersensitivity to any of the components in the faricimab injection, dilating eye drops, or any of the anesthetics and antimicrobial preparations used by the patient during the study
Any major illness or major surgical procedure within 1 month before the Day 1. One re-screening for this criterion is permitted
History of other diseases, other non-diabetic metabolic dysfunction, physical examination finding, historical or current clinical laboratory finding giving reasonable suspicion of a condition that contraindicates the use of the faricimab or that might affect interpretation of the results of the study or renders the patient at high-risk for treatment complications, in the opinion of the Investigator
Active cancer within the past 12 months prior to Day 1 except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, and prostate cancer with a Gleason score of ≤6 and a stable prostate-specific antigen for >12 months
Stroke or myocardial infarction within 12 months prior to the Day 1. One re-screening for this criterion is permitted
Any febrile illness within 1 week prior to Day 1. One re-screening for this criterion is permitted
Pregnant or breastfeeding, or intending to become pregnant during the study or within 3 months after the final dose of faricimab
Renal failure requiring renal transplant, hemodialysis, or peritoneal dialysis within 6 months prior to Day 1 or anticipated to require hemodialysis or peritoneal dialysis at any time during the study
Any condition resulting in a compromised immune system that is likely to impact the aqueous humor (AH) inflammatory biomarkers
Patients who are currently enrolled in or have participated in any other clinical study involving an investigational product or device, or in any other type of medical research, within 3 months or 5 half-lives prior to Day 1 and up to completion of the current study
Substance abuse occurring within 12 months prior to screening, in the Investigator's judgment
Use of systemic immunomodulatory treatments within 6 months or 5 half-lives prior to Day 1
Use of any systemic corticosteroids (including inhaled corticosteroids from inhalers used regularly, e.g., pulmonary disease, asthma, or seasonal allergy) within 1 month prior to Day 1
Any prior or concomitant systemic anti-VEGF treatment within 6 months or 5 half-lives prior to Day 1
Use of systemic medications known to be toxic to the lens, retina or optic nerve used during the 6-month period or 5 half-lives prior to Day 1 or likely need to be used
Received a blood transfusion within 3 months prior to the screening visit
Received any treatment that leads to immunosuppression within 6 months or 5 half-lives prior to Day 1
Ocular Exclusion Criteria for Study Eye
High-risk PDR. This exclusion criterion is to be assessed by the CRC
Any history of or ongoing rubeosis iridis
Any panretinal photocoagulation or macular laser photocoagulation treatment received in the study eye prior to the screening visit or expected to be received between the screening visit and Day 1
Any history of treatment with anti-VEGF or any periocular or IVT corticosteroids in the study eye and no such treatment planned for the time between screening and Day 1
Any treatment for dry eye disease in the last month prior to Day 1. Lubricating eye drops and ointments are permitted
Any treatment with anti-inflammatory eye drops within 1 month prior to Day 1
Any intraocular surgery within 3 months prior to Day 1 or any planned surgery during the study
History of vitreoretinal surgery/pars plana vitrectomy, corneal transplant, or radiotherapy
Any active or suspected ocular or periocular infections on Day 1
Any glaucoma surgery/laser procedure involving the iris, trabecular meshwork, or ciliary body prior to the screening visit. Only iris surgery/laser might be allowed if they occurred more than 6 months prior to Day 1
Any presence of active intraocular inflammation on Day 1 or any history of intraocular inflammation
Any history of idiopathic, infectious, or noninfectious uveitis
Any current or history of ocular disease other than DME that may confound assessment of the macula or affect central vision
Any current ocular condition or other causes of visual impairment for which, in the opinion of the Investigator, VA loss would not improve from resolution of macular edema
Ocular Exclusion Criteria for Fellow Eye
Any previous treatment with Iluvien® or Retisert® in the non-study eye
Patient is currently receiving treatment with brolucizumab or bevacizumab in the non-study eye and is unwilling to switch to a protocol allowed non-study eye treatment during the study
Non-functioning non-study eye
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note